Association of p53 and p21 polymorphisms with prostate cancer

Sivoňová,Monika  Kmeťová; Vilčková,Marta; Kliment,Ján; Mahmood,Silvia; Jurečeková,Jana; Dušenková,Svetlana; Waczulíková,Iveta; Slezák,Peter; Dobrota,Dušan

doi:10.3892/br.2015.496

Association of p53 and p21 polymorphisms with prostate cancer

Authors:
- Monika Kmeťová Sivoňová
- Marta Vilčková
- Ján Kliment
- Silvia Mahmood
- Jana Jurečeková
- Svetlana Dušenková
- Iveta Waczulíková
- Peter Slezák
- Dušan Dobrota
View Affiliations

Affiliations: Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovak Republic, Department of Urology, Comenius University in Bratislava, Jessenius Faculty of Medicine and UHM, 036 01 Martin, Slovak Republic, Department of Nuclear Physics and Biophysics, Division of Biomedical Physics, Comenius University, Faculty of Mathematics, Physics and Informatics, 842 48 Bratislava, Slovak Republic, Institute of Simulation and Virtual Medical Education, Comenius University, Faculty of Medicine, 813 72 Bratislava, Slovak Republic
Published online on: July 27, 2015 https://doi.org/10.3892/br.2015.496
Pages: 707-714

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene‑gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction‑restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27‑0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate‑specific antigen levels (P>0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36‑0.93; P<0.05) in non‑smokers compared to the non‑smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51‑17.15) compared to the non‑smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.

View Figures

View References

1	Ondrusova M, Ondrus D, Karabinos J, Muzik J, Kliment J and Gulis G: Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics. Tumori. 97:149–155. 2011.PubMed/NCBI
2	Glass AS, Cary KC and Cooperberg MR: Risk-based prostate cancer screening: Who and how? Curr Urol Rep. 14:192–198. 2013. View Article : Google Scholar : PubMed/NCBI
3	DrudgeCoates L and Turner B: Prostate cancer overview. Part 1: Non-metastatic disease. Br J Nurs. 21 (Suppl 9):S23–S28. 2012. View Article : Google Scholar
4	Sivoňová MK, Dobrota D, Dušenka R, Waczulíková I, Slezák P, Matáková T, Mahmoodová S, Mištuna D and Kliment J: Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population. Mol Biol Rep. 39:7871–7880. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sivonova MK, Dobrota D, Matakova T, Dusenka R, Grobarcikova S, Habala V, Salagovic J, Tajtakova M, Pidanicova A, Valansky L, et al: Microsomal epoxide hydrolase polymorphisms, cigarette smoking and prostate cancer risk in the Slovak population. Neoplasma. 59:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
6	Pietsch EC, Humbey O and Murphy ME: Polymorphisms in the p53 pathway. Oncogene. 25:1602–1611. 2006. View Article : Google Scholar : PubMed/NCBI
7	Inoue K, Kurabayashi A, Shuin T, Ohtsuki Y and Furihata M: Overexpression of p53 protein in human tumors. Med Mol Morphol. 45:115–123. 2012. View Article : Google Scholar : PubMed/NCBI
8	Mirzayans R, Andrais B, Scott A and Murray D: New insights into p53 signaling and cancer cell response to DNA damage: Implications for cancer therapy. J Biomed Biotechnol. 2012:1703252012. View Article : Google Scholar : PubMed/NCBI
9	ElDeiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
10	Kaul R, Mukherjee S, Ahmed F, Bhat MK, Chhipa R, Galande S and Chattopadhyay S: Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. Int J Cancer. 103:606–615. 2003. View Article : Google Scholar : PubMed/NCBI
11	Suzuki H, Ito R, Ikeda K and Tamura TA: TATA-binding protein (TBP)-like protein is required for p53-dependent transcriptional activation of upstream promoter of p21Waf1/Cip1 gene. J Biol Chem. 287:19792–19803. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 1:639–649. 2002.PubMed/NCBI
13	Brosh R and Rotter V: When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
14	Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 7:961–963. 1987.PubMed/NCBI
15	Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
16	Robles AI, Linke SP and Harris CC: The p53 network in lung carcinogenesis. Oncogene. 21:6898–6907. 2002. View Article : Google Scholar : PubMed/NCBI
17	Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI
18	Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 25:3489–3500. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhang JN, Yi SH, Zhang XH, Liu XY, Mao Q, Li SQ, Xiong WH, Qiu YM, Chen T and Ge JW: Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma. Genet Mol Res. 11:3618–3628. 2012. View Article : Google Scholar : PubMed/NCBI
20	Sucheston L, Witonsky DB, Hastings D, Yildiz O, Clark VJ, Di Rienzo A and Onel K: Natural selection and functional genetic variation in the p53 pathway. Hum Mol Genet. 20:1502–1508. 2011. View Article : Google Scholar : PubMed/NCBI
21	Quiñones LA, Irarrázabal CE, Rojas CR, Orellana CE, Acevedo C, Huidobro C, Varela NE and Cáceres DD: Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: An exploratory genotype-environment interaction study. Asian J Androl. 8:349–355. 2006. View Article : Google Scholar : PubMed/NCBI
22	Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, et al: A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 10:430–435. 2003. View Article : Google Scholar : PubMed/NCBI
23	Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ and Chen WC: p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int. 73:41–46. 2004. View Article : Google Scholar : PubMed/NCBI
24	Mittal RD, George GP, Mishra J, Mittal T and Kapoor R: Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India. Arch Med Res. 42:122–127. 2011. View Article : Google Scholar : PubMed/NCBI
25	Lu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y, Wang J, Xie L, Li T, Qin X, et al: Association of p53 codon 72 polymorphism with prostate cancer: An update meta-analysis. Tumour Biol. 35:3997–4005. 2014. View Article : Google Scholar : PubMed/NCBI
26	RicksSanti L, Mason T, Apprey V, Ahaghotu C, McLauchlin A, Josey D, Bonney G and Dunston GM: p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate. 70:1739–1745. 2010.PubMed/NCBI
27	Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E and Eiguchi K: Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5:152005. View Article : Google Scholar : PubMed/NCBI
28	Salehi Z and Hadavi M: Analysis of the codon 72 polymorphism of TP53 and human papillomavirus infection in Iranian patients with prostate cancer. J Med Virol. 84:1423–1427. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhang J, Zhuo WL, Zheng Y and Zhang YS: Polymorphisms of TP53 codon 72 with prostate carcinoma risk: A meta-analysis. Med Oncol. 27:540–546. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhu Y, Wang J, He Q and Zhang JQ: Association of p53 codon 72 polymorphism with prostate cancer: A meta-analysis. Mol Biol Rep. 38:1603–1607. 2011. View Article : Google Scholar : PubMed/NCBI
31	Ma H, Zhou Z, Wei S and Wei Q: Association between p21 Ser31Arg polymorphism and cancer risk: A meta-analysis. Chin J Cancer. 30:254–263. 2011. View Article : Google Scholar : PubMed/NCBI
32	Gravina S, Lescai F, Hurteau G, Brock GJ, Saramaki A, Salvioli S, Franceschi C and Roninson IB: Identification of single nucleotide polymorphisms in the p21 (CDKN1A) gene and correlations with longevity in the Italian population. Aging (Albany NY). 1:470–480. 2009.PubMed/NCBI
33	Liu F, Li B, Wei Y, Chen X, Ma Y, Yan L and Wen T: p21 codon 31 polymorphism associated with cancer among white people: Evidence from a meta-analysis involving 78,074 subjects. Mutagenesis. 26:513–521. 2011. View Article : Google Scholar : PubMed/NCBI
34	Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR and Wei Q: Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 26:1596–1602. 2005. View Article : Google Scholar : PubMed/NCBI
35	Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, et al: p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 13:2217–2224. 2004.PubMed/NCBI
36	Taghavi N, Biramijamal F, Abbaszadegan MR, Khademi H, Sotoudeh M and Khoshbakht S: P21(waf1/cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: A preliminary study. Arch Iran Med. 13:235–242. 2010.PubMed/NCBI
37	Wigginton JE, Cutler DJ and Abecasis GR: A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet. 76:887–893. 2005. View Article : Google Scholar : PubMed/NCBI
38	Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA and Beer TM: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 49:263–266. 2001. View Article : Google Scholar : PubMed/NCBI
39	Shen H, Zheng Y, Sturgis EM, Spitz MR and Wei Q: P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Lett. 183:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
40	Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD and Moriuchi T: Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis. 22:515–517. 2001. View Article : Google Scholar : PubMed/NCBI
41	Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:574–578. 1994. View Article : Google Scholar : PubMed/NCBI
42	Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
43	Moffatt KA, Johannes WU, Hedlund TE and Miller GJ: Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res. 61:7122–7129. 2001.PubMed/NCBI
44	Facher EA, Becich MJ, Deka A and Law JC: Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 79:2424–2429. 1997. View Article : Google Scholar : PubMed/NCBI
45	Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT and Honn KV: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene. 11:1395–1398. 1995.PubMed/NCBI
46	Chedid M, Michieli P, Lengel C, Huppi K and Givol D: A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 9:3021–3024. 1994.PubMed/NCBI
47	Sivoňová MK, Vilčková M, Jurečeková J, Hatok J, Dobrota D, Dušenka R and Kliment J: The role of p21 3′UTR gene polymorphism in the risk of prostate cancer: A pilot study. Mol Med Rep. 7:986–990. 2013.PubMed/NCBI
48	Kibel AS, Suarez BK, Belani J, Oh J, Webster R, BrophyEbbers M, Guo C, Catalona WJ, Picus J and Goodfellow PJ: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 63:2033–2036. 2003.PubMed/NCBI
49	Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, Yu CC, Wu TT, Huang CH, Wu WJ, et al: Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res. 13:6632–6638. 2007. View Article : Google Scholar : PubMed/NCBI
50	Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML and Kantoff PW: Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 16:5244–5251. 2010. View Article : Google Scholar : PubMed/NCBI
51	Kometani T, Yoshino I, Miura N, Okazaki H, Ohba T, Takenaka T, Shoji F, Yano T and Maehara Y: Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett. 278:27–33. 2009. View Article : Google Scholar : PubMed/NCBI